Truemeds, the Mumbai-based telehealth and e-pharmacy platform, has closed an $85 million Series C funding round, cementing its position as one of the fastest-scaling players in India’s chronic care medicine segment. The round was led by Accel and Peak XV Partners, with continued backing from WestBridge Capital and Info Edge Ventures.
The fresh capital includes $65 million in primary infusion for expansion and $20 million in secondary share sales, allowing early investors to exit. Founded in 2019 by Akshat Nayyar and Dr Kunal Wani, the company aims to aggressively widen its national presence, scaling its fulfillment network from 19 to 50 centers within the next 12 months. It also plans to set up a technology hub in Bengaluru, hire across engineering and product teams, and introduce diagnostic services in the coming months.
Targeting India’s planned-care market, Truemeds focuses on patients managing long-term conditions like diabetes, hypertension and cardiovascular diseases. Its model offers clinically approved, lower-cost alternatives to branded drugs, claiming to cut monthly medicine bills by 50 to 70 percent. The platform currently handles about 600,000 orders a month and connects with roughly 600 doctors every day, with a growing share of its user base coming from non-metro regions.
Co-founder and CEO Nayyar said the company’s goal is to make quality medicines affordable for every patient in the country, particularly in regions where access remains limited. The new funding, he added, would strengthen operations and deepen penetration into underserved markets.
Accel partner Abhinav Chaturvedi noted that affordability remains a critical challenge in India’s healthcare sector, despite rapid modernization. Peak XV’s managing director Sakshi Chopra called Truemeds’ approach “transformative” for chronic care delivery, highlighting its ability to blend technology, clinical expertise and logistics to bring essential medicines to millions who need them most.
